Elizabeth C Reuman
Affiliation: Stanford University
- Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vectorElizabeth C Reuman
Department of Medicine, Stanford University School of Medicine, Division of Infectious Diseases, 300 Pasteur Drive, Grant Building, Room S 146, Stanford, CA 94305, USA
Antimicrob Agents Chemother 54:934-6. 2010..Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clinically relevant raltegravir-resistant variants...
- Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutationsElizabeth C Reuman
Division of Infectious Diseases, Department of Medicine, Stanford University, 300 Pasteur Drive, Grant S 146, Stanford, CA 94305, USA
J Antimicrob Chemother 65:1477-85. 2010....
- Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatmentSeverine Margeridon-Thermet
Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, California, USA
Antimicrob Agents Chemother 57:343-9. 2013..001). The likelihood of detecting a LAM resistance mutation was significantly increased using UDPS compared to Sanger sequencing and was inversely associated with the time since LAM discontinuation...
- A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing readsElizabeth C Reuman
Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA
Bioinformatics 26:2929-32. 2010....